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INTRODUCTION 
Jaundice is the most common clinical sign in neonatal medicine, but rarely is it the 
harbinger of disease or associated with neurotoxicity. Some two-thirds of healthy term infants 
and almost all premature infants develop clinical jaundice in the first week of life
1
. Majority of 
this jaundice is physiological and results from an immature liver‟s excretory pathway for 
bilirubin at the time of its heightened production. In the current era of early postnatal discharge, 
jaundice is currently the most common reason for readmission to the hospital in the first week of 
life in western countries
2
. 
Concepts of bilirubin toxicity remain highly controversial. The problem is that bilirubin 
levels that are toxic to one infant may not be toxic to another, or even to same infant in different 
clinical circumstances. Currently, major debate surrounds the toxicity of bilirubin in otherwise 
healthy term infants and in premature, low birth weight infants
5
. 
Although all infants experience some degree of hyperbilirubinemia in the first few days 
of life and most have physiological jaundice, the extent and duration of the elevation vary among 
populations of different races in different geographic distributions
6
. 
 This study was conducted to know the audiological and developmental outcomes of 
normal risk term newborns with serum total bilirubin of 20 mg/dl or more, who have had 
intervention for management of hyperbilirubinemia and had no neurological abnormality by 
clinical examination during their stay in the hospital. 
 10 
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REVIEW OF LITERATURE 
Jaundice is the visible manifestation in the skin and sclera due to elevated serum 
concentration of bilirubin. Most adults are jaundiced when serum total bilirubin (STB) levels 
exceed 2.0mg/dl (34 micromol/dl). Neonates may not appear jaundiced until serum total bilirubin 
concentration exceeds 5mg/dl-7mg/dl
6
. Chemical hyperbilirubinemia defined as serum total 
bilirubin of 2mg/dl is virtually universal in newborns during first week of life. Serum total 
bilirubin concentration in premature infants is even higher, persists longer and are more likely to 
be associated with neurological injury than term infants. 
Yellowish discoloration is first evident on the skin of the face, nasolabial fold and the tip 
of the nose. It is masked by the physiological plethora of the newborn and can be brought out by 
blanching the skin so that underlying yellowness of the subcutaneous tissues and blood vessels 
can be visualized.  The jaundice must be looked for in good day light and there should be no 
yellow clothes or curtains in the background which can lead to an error of over estimation. 
 Neonatal jaundice is classified as physiological and pathological. This latter entity has 
been called nonphysiologic, although frequently no disease is identified as the cause. 
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CRITERIA THAT RULE OUT THE DIAGNOSIS OF PHYSIOLOGIC 
JAUNDICE
6 
1. Clinical jaundice in the first 24 hours of life. 
2. Serum total bilirubin (STB) concentration increasing by more than 0.2mg/dl/hr or 
5mg/dl/day. 
3. Clinical jaundice persisting for more than 2 weeks in a full term infant. 
4. Direct serum bilirubin concentration exceeding 1.5-2 mg/dl. 
Physiologic jaundice can be divided into 2 phases
5
. Phase I includes the first 5 days of 
life in term infants and is characterized by rapid increase in STB levels for 3-4 days, after which 
the levels begin to decline. Phase II is characterized by stable, but elevated STB levels lasting for 
about 2 weeks. In contrast, in preterm infants, phase I lasts for 6-7 days, and STB levels reached 
are higher than those in term infants. After phase II, STB levels become comparable to adult 
levels. 
The levels usually rise in full term infants to a peak of 6-8 mg/dl by 3 days of age and 
thereafter fall. A rise to 12mg/dl is in the physiological range. In premature infants, peak may be 
10-12 mg/dl on the fifth day of life, possibly rising to more than 15mg/dl without any specific 
abnormality of bilirubin metabolism. 
PHYSIOLOGIC MECHANISMS 
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Distinctive aspects of normal newborn physiology that contribute to neonatal 
hyperbilirubinemia include: 
1. Increased bilirubin synthesis 
2. Less effective binding and transportation 
3. Less efficient hepatic conjugation and excretion 
4. Enhanced absorption of bilirubin via enterohepatic circulation. 
INCREASED BILIRUBIN SYNTHESIS 
Bilirubin is a breakdown product of hemoglobin. The bilrubin load is greater in neonates 
because hemoglobin breakdown is two to three times the adult rate and also there is an increase 
in red blood cells degradation in the marrow even before its release. In addition, bilirubin 
synthesis in healthy neonates results from greater erythrocyte mass at birth and neonatal red 
blood cells have a shorter half life compared to adults. The life span of RBCs is less than 70 days 
for premature infants, 70- 90 days for healthy term infants compared to 120 days in adults. 
BINDING AND TRANSPORT 
Circulating bilirubin is bound to plasma albumin. It is believed that neuro toxicity 
associated with hyperbilirubinemia is primarily the result of unbound or “free” bilirubin, so the 
amount of albumin available for binding is important. A full term infant has lower plasma 
albumin level than adult and so fewer binding sites for binding the bilirubin. 
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CONJUGATION AND EXCRETION 
The conjugating capacity of normal infants varies greatly, with delayed conjugation and 
excretion, in some cases, related to the immaturity of the liver cell itself. The activity of uridine 
diphosphate-glucuronyltransferase (UGT) system in the newborn must be induced. Elevated 
conjugated bilirubin levels at birth, in cases of severe fetal hemolysis, suggest that STB levels 
may be necessary to induce the conjugating enzymes. 
ENHANCED ENTEROHEPATIC CIRCULATION 
Intestinal absorption of bilirubin successfully excreted into the intestine is enhanced by 
several features of newborn physiology, thereby adding the tendency of newborns to become 
jaundiced. Conjugated bilirubin as monoglucuronide or diglucuronide is unstable and can be 
spontaneously or enzymatically hydrolysed to unconjugated bilirubin which can easily be 
reabsorbed in the intestinal mucosa. In addition absorption is enhanced by the sterility of 
intestinal contents. Older children and adults have intestinal flora which can metabolize 
conjugated bilirubin to the readily excretable breakdown products of urobilin and stercobilin. 
Moreover increased levels of β- glucuronidase can deconjugate bilirubin to form more 
unconjugated bilirubin which can be absorbed by enterohepatic circulation. Mild alkaline pH and 
the predominance of monoglucuronides as the main excretion form of bilirubin in the first few 
days of life of neonate also contributes for increased bilirubin levels.  
  
 15 
 
CLINICAL SIGNIFICANCE 
All of the above mentioned factors have a combined effect on potentially increasing 
serum total bilirubin levels in healthy newborn and a premature baby is even more susceptible.  
Any pathological process that increases the production or impairs the elimination of bilirubin can 
exacerbate the normally occurring physiologic jaundice in newborns. In clinical settings such 
pathologic disorder should be treated appropriately. What remains controversial is the danger 
posed by increased serum total bilirubin levels encountered in the absence of pathologic 
disorders
6
.  
BREAST-MILK JAUNDICE 
Breast-milk jaundice is of late onset and has an incidence in term infants of  
2%- 4%
5
. Instead of a fall in bilirubin value by day 4, the bilirubin level continues to rise and 
may reach 20 to 30 mg/dl by 14 days of age. If breast feeding is continued the bilirubin level stay 
elevated and then falls slowly returning to normal by 4 to 12 weeks. If breast feeding is stopped 
the bilirubin value will fall rapidly in 48 hours. The mechanism of breast-milk jaundice is 
unknown but is thought to be due to unidentified factors in breast milk interfering with bilirubin 
metabolism. Some factors attributed for the cause are pregnane-3α,20β-diol and  
β-glucuronidase which has not yet been proved.  
These infants show good weight gain, have normal liver function test results and show no 
evidence of hemolysis. 
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BREAST-FEEDING JAUNDICE 
 Infants who are breast fed have higher bilirubin levels after day 3 of life compared to 
formula fed infants. The differences in the levels of bilirubin are usually not clinically 
significant. The incidence of peak bilirubin levels of more than 12mg/dl in breast fed term 
infants is 12% to 13%
5
. The main factor thought to be responsible for breast feeding jaundice is a 
decreased intake of milk that leads to increased enterohepatic circulation. 
UNCONJUGATED HYPERBILIRUBINEMIA 
Overproduction of bilirubin combined with immature mechanism for conjugation and 
enhanced intestinal enterohepatic circulation of bilirubin contributes to the development of 
neonatal jaundice. 
CAUSES OF UNCONJUGATED HYPERBILIRUBINEMIA
6 
A. Excessive production of bilirubin (hemolytic disease of newborn) 
1. Blood group heterospecificity (incompatibility) 
a. Rh isoimmunization 
b. ABO incompatibility 
c. Minor blood group incompatibility  
2. Red blood cell enzyme abnormality 
a. Glucose-6-phosphate dehydrogenase deficiency 
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b. Pyruvate kinase deficiency 
3. Sepsis  
4. Red blood cell membrane defects 
a. Hereditary spherocytosis 
b. Elliptocytosis 
c. Poikilocytosis 
B. Impaired conjugation or excretion 
1. Hormonal deficiency 
a. Hypothyroidism 
b. Hypopituitarism 
2. Disorders of bilirubin metabolism 
a. Crigler-Najjar syndrome type I 
b. Crigler- Najjar Syndrome type II ( Arias syndrome) 
c. Gilbert disease 
d. Lucey –driscoll syndrome 
3. Enhanced enterohepatic circulation 
a. Intestinal obstruction, pyloric stenosis 
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b. Ileus, meconium plug, cystic fibrosis 
BILIRUBIN TOXICITY
 
Excessive bilirubin appears to be a generalized cellular poison
1
. Disruption of membrane 
function, lowering of action potentials, compromise of energy metabolism, and disturbance of 
neurotransmitter synthesis and neurotransmission are some of the causes which have been 
implicated
3
. 
Neuronal vulnerability to bilirubin would appear to be both gestational and postnatal 
dependent, possibly reflecting the functional status of the blood brain barrier in the specific area 
of the brain at the time of the metabolic insult. There is a growing evidence to suggest that the 
substrate for P-glycoprotein, a plasma membrane efflux pump found on the luminal surface of 
the brain capillary endothelial cells is considered responsible for limiting entry of certain 
lipophilic substrates into the CNS
4
. P- Glycoprotein expression has been related to gestational 
maturity, and may be a factor contributing to the greater vulnerability of the premature brain to 
bilirubin toxicity. 
FACTORS THAT INCREASE SUSCEPTIBILITY TO NEUROTOXICITY 
ASSOCIATED WITH HYPERBILIRUBINEMIA 
1. Asphyxia 
2. Hyperthermia 
3. Septicemia 
4. Hypoalbuminemia 
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5. Acidosis 
6. Caloric deprivation 
7. Prolonged hyperbilirubinemia 
8. Young gestational age 
9. Low birth weight 
10. Excessive hemolysis 
Attempts to reproduce bilirubin neurotoxicity experimentally in animals point to the 
importance of coexisting risk factors (such as acidosis, hypoxia, hypercarbia and blood-brain 
barrier disruption) as being prerequisites for bilirubin toxicity. Agents that interfere with the 
binding of bilirubin to serum albumin also promote neurotoxicity
1
. 
THEORIES FOR MECHANISMS OF BILIRUBIN TOXICITY 
1. One hypothesis is that lipophilic nature of free bilirubin, on equibilirium with bound 
bilirubin has access to tissues. Thus when free bilirubin level increases, the levels 
also increase within the brain tissue saturating membranes and causing precipitation 
of bilirubin within the nerve cell membrane
6
. 
        This hypothesis arose to explain the outbreak of kernicterus in premature infants 
given sulfisoxazole
8
. 
2. Second hypothesis involves the binding of bilirubin to albumin but also focuses the 
state of bilirubin available to cross cell membranes. At alkaline pH bilirubin forms a 
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water-soluble sodium salt, but the solubility of this substance at neutral or low pH is 
extremely low. Bilirubin is therefore found in plasma as a dianion bound to albumin 
after dissociation of two hydrogen ions. Bilirubin acid tends to precipitate readily 
from serum only when the lipid membrane is present suggesting that a 
supersaturation level of bilirubin acid precipitates in the tissues of icteric infants. 
This theory provides an explanation for the role that acidosis may play in the 
development of kernicterus
6
. 
3. Third theory suggests that bound bilirubin enters brain mainly through damaged 
blood brain barrier. The importance of a mature blood brain barrier stems from 
demonstration that the barrier to albumin and bilirubin can be reversibly opened 
under conditions of vascular injury, abnormal circulation, abnormal osmolarity, 
hyperthermia and septicemia
6
. 
4. Recent studies suggest unconjugated bilirubin is a substrate for  
P- glycoprotein and that the Blood-Brain barrier P-glycoprotein may play a role in 
limiting the passage of bilirubin into the CNS
9, 10
. 
CLINICAL BILIRUBIN ENCEPHALOPATHY 
The word „Kernicterus‟ originated as a description of yellow nuclear staining of the brain 
but has become synonymous with acute and chronic interference with membrane activity and 
neurological features of what are more correctly termed bilirubin encephalopathy and its 
sequelae. Three stages have been identified
5
;  
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1. Stage 1(Early phase) – characterized by hypotonia, lethargy, high pitched cry, and 
poor suck. 
2. Stage 2(Intermediate phase) - Hypertonia of the extensor muscles (with 
opisthotonus, rigidity, oculogyric crisis, and retrocollis) irritability, fever and may 
have seizures. Many infants die in this phase. All infants who survive this phase 
develop chronic bilirubin encephalopathy (clinical diagnosis of Kernicterus) 
3. Stage 3 (Advanced phase)-Pronounced opisthotonus (hypotonia replaces hypertonia 
approximately after one week of age) shrill cry, apnea, seizures, coma and death.  
 
CHRONIC BILIRUBIN ENCEPHALOPATHY 
The long term features of bilirubin encephalopathy include extrapyramidal disturbances, 
auditory impairment, upward gaze palsies, dental and enamel dysplasia. The resulting cerebral 
palsy typically has an element of athetosis which can develop as early as 18 months or may be 
delayed for several years. High- frequency sensorineural deafness frequently accompanies the 
cerebral palsy, but may evolve in isolation. Cognitive impairment may occur in bilirubin 
encephalopathy. 
PREDICTING ENCEPHALOPATHY AND REVERSIBILITY OF 
DAMAGE: 
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 Despite progress made in the clinical management, there is no agreement on what 
constitutes the “safe” level of bilirubin. 
BRAINSTEM EVOKED RESPONSE AUDIOMETRY: 
 Brainstem Evoked Response Audiometry (BERA) is also called as Auditory Brainstem 
Evoked Response (ABER) or Auditory Brainstem Response (ABR). 
Hyperbilirubinemia affects the auditory pathway causing high frequency hearing loss and 
frequently in accompanied by cerebral palsy. Since hearing loss is the clinical problem there is a 
need for accurate assessment of auditory function in infants, young children and person with 
diminished capacity to reveal their hearing loss. The incidence of moderate to profound hearing 
loss in high risk infants is reported to be 2.5-5% compared to 1%in normal infants
 23
. 
Among the first clinical application of Brainstem Evoked Response (BER) was the 
prediction of hearing loss (screening) in infants and young children. First reports of systemic 
recordings in young infant came around mid 1970s. Since then BERA has been suggested as a 
screening tool that could identify or predict early effects of hyperbilirubinemia on the central 
nervous system. 
BERA is accurate and non invasive with sensitivity of 100% and specificity of 90.8%
29
. 
 BERA consists of series of seven positive to negative going waves, occurring within 10 
milliseconds of stimulus onset
31
. Several system of nomenclature has been devised for the 
naming of waves but the most commonly used is to label the positive waves in roman numerals 
from I to VII. The full component of seven waves is not always present in BERA testing. A 
normal variant is absence of wave II, VI and especially VII
31
.  
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 BERA is recorded with electrodes attached to various parts of the head. The electrodes 
are small cups or discs coated with various materials such as silver, silver chloride and tin. The 
waves are generated due to the electrical difference generated between the two electrodes
31
. 
PROCEDURE: 
The test should be carried out in a sound proof room and the infant should ideally sleep 
which can usually be attained after a good feed. In rare instances the infant can be sedated with 
oral Triclofos 50mg/kg 30 minutes before the procedure
23
. To measure the electrical pulses, 
small monitoring electrodes are placed on the scalp. 
Electrodes: 
 BERA is recorded from various electrodes attached to various positions on the head. 
 First electrode (noninverting electrode) is placed on the vertex (top of the head) or at 
the middle of the forehead just below the hairline. 
 Second electrode is placed on the earlobe or mastoid of the ipsilateral ear that is 
receiving the stimulus. 
 Third electrode is typically placed on the contralateral earlobe, contralateral mastoid, 
forehead or nape of the neck and serves as a ground electrode. 
Before attaching the electrodes the skin must be thoroughly cleaned to remove excess oil, 
dead skin, and dirt to get good control. 
STIMULUS TYPE:  
CLICK AND BURST
31
: 
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 Two types of stimulus are used to generate waves in BERA. 
1. Click 
2. Burst  
Click was used in this study. In using BERA to assess the integrity of central auditory 
pathway click stimuli are generally used because they elicit the clearest wave forms. A sound 
stimulus is introduced to the infant and the wave pattern generated as electrical impulse through 
the auditory pathway is measured. Recorded parameters include threshold sensitivity, latency, 
the interpeak latency, amplitude of the waves, slope of the latency changes with time and 
magnitude of the stimulus. Interpeak latencies I-III and I-V are useful in assessing damage 
from bilirubin
6
. 
Brief tone bursts are used when assessing hearing sensitivity in different frequency 
regions.  
 
Table – 1:   BERA- Waves and area of generation31 
 
 
Wave forms generators 
I 
II 
III 
IV 
V 
VIII nerve 
Cochlear nucleus 
Superior olivary nucleus    
 Lateral lemniscus 
Inferior colliculus 
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Figure 1: BERA- Waves
31 
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Table 2:  normal values in BERA
30 
 
 
 
Wave form 
 
Normal value 
(msec) 
 
Standard deviation 
 
I 
II 
III 
IV 
V 
I-III 
III-V 
I-V 
 
1.6 
2.8 
3.7 
5.1 
5.6 
2.0 
1.8 
3.8 
 
0.2 
0.2 
0.2 
0.2 
0.2 
0.4 
0.4 
0.4 
 
 Bilirubin toxicity causes reversible hearing loss, as shown by various studies which show 
that the BERA abnormality reduces or even normalizes on repeatedly following up the child
27, 14
. 
TRIVANDRUM DEVELOPMENTAL SCREENING CHART 
 Trivandrum developmental screening chart (TDSC) is a screening tool based on 
17 selected items from BSID- Baroda Norms (Bailey scale of infant 
development).  
 27 
 
  Each milestone is given a range. The left hand side of the each item represents 
the age at which 3% of the children would have passed the test and the right end 
represents 97% passing the test. 
 
 The following milestones are used to identify developmental delay in Triandrum 
developmental Screening Chart. 
1. Social smile 
2. Eyes follow pen/pencil 
3. Holds head steady 
4. Rolls from back to stomach 
5. Turns head to sound of bell or rattle 
6. Transfers objects hand to hand 
7. Raises itself to sitting position 
8. Standing up by furniture 
9. Fine prehension pellet 
10. Pat a cake 
11. Walks with help 
12. Throws ball 
13. Walks alone 
14. Says two words 
15. Walk backwards 
16. Walk upstairs with help 
17. Points to parts of doll ( 3 parts) 
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 The test was designed in Child Developmental Centre, SAT Hospital,Trivandrum. 
 It can be used up to 24 months of age. 
 Sensitivity of the test is 67% and specificity 79%22. 
 It is widely used as a screening test. 
 A vertical line is drawn for the chronological age and if the child fails to attain 
any of the milestones that falls short on left hand side of the vertical line then it is 
considered to be a developmental delay.  
 Any obvious asymmetry or abnormality is also considered abnormal. 
Very few studies have included normal, term newborns with hyperbilirubinemia as the 
study population even though there are many studies about the auditory evaluation in newborns 
with hyperbilirubinemia. 
 A study on Hearing status in neonatal hyperbilirubinemia with Auditory Bainstem 
Response and Otoacoustic Emission test conducted by Baradaranfar et al
11 
which included 35 
term newborns with hyperbilirubinemia of more than 20 mg/dl found that 26/35 were normal and 
9/35 were abnormal (25.7%). 
Another study was conducted by Lofti  et al
12
  to know the prevalence of late 
sensorineural loss in children with history of severe hyperbilirubinemia. It was a cohort study 
involving 102 children. They found that 6.9% had mild hearing loss and 7.8 % had moderate and 
7.8% had severe hearing loss and the BERA abnormality was found to be 22.5%. 
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A study conducted by N Y Boo  et al
13
at KualaLumpur showed that the BERA 
abnormality was 22% in their study population which included 128 newborns who had serum 
bilirubin of more than 20 mg/dl (>339µmol/l).  
In another follow up study, in which follow up was done for 5 years, conducted in China 
by Chen W X  et al
14
 among new born with jaundice it was found that the BERA abnormality in 
hemolytic group of jaundice patients was 10% (3/29) at the end of about 3 months (median time 
interval of the study was 3.2 months) and in non-hemolytic group was 9.1% (9/99). After two 
years when BERA was repeated in this study population it was found that BERA returned to 
normal in all except 3 cases. All except 5 among the 128 had a normal neurodevelopmental 
outcome. They found that the affected cases had only mild motor delay and hypotonia which also 
returned to normal at 3 years of age. No relation was found between an abnormal initial BERA 
and the  final neurodevelopmental outcome. They concluded that the effect of 
hyperbilirubinemia is only transient in their population. 
In a study conducted in the Department of Pediatrics in PGIMER, Chandigarh
15
in babies 
who had undergone double exchange transfusion for hyperbilirubinemia it was found that 
bilirubin abnormality was found in 76% of the cases. Newborns with gestational age more than 
35 weeks were involved in the study and the mean serum bilirubin was 37 mg/dl. MRI was 
abnormal in 61% of the babies. At the end of one year DDST was used for developmental 
assessment and 60% were found to be affected. 
A study done in Lucknow by Agarwal V K  et al
16
found that among 30 term infants with 
hyperbilirubinemia BERA abnormality was noted in 56.7% during the initial visit. In 10 cases 
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the changes reverted on follow up. Three of them were found to have developmental delay when 
tested by Denver Developmental Screening Test (DDST) at one year of age. 
In one another study done in Jaipur
17
 in which BERA recording was done in 30 newborns 
abnormality obtained was 73.3 % and the abnormality persisted in 23.3% of them on follow up. 
Various studies have been made to find out whether there is any association with high 
bilirubin levels and BERA abnormality.  Studies by Mukhopadhyay
15
 and Agarwal et al
16
 
showed a significant association between high bilirubin values and BERA abnormality. There 
are also studies conducted by Ziang ZD  et al
24 
which found no association between the two 
factors. 
A study was conducted in England
17
 to know the outcomes among newborns who had 
bilirubin values of more than 25 mg/dl who were treated with phototherapy and exchange 
transfusion. They were followed up for 2 years and were found to have no adverse 
neurodevelopmental outcome. 
In one of the studies conducted by Psarommatis et al
18
 to know about the frequency of 
reversible Auditory Brain Stem Responses in screening failure in high risk newborns 1294 high 
risk neonatal records were reviewed. It was found that 13.8% have demonstrated abnormal 
hearing recordings in the initial screening. 64.2% of them had complete recovery and 15% had 
partial recovery. It concluded that this phenomenon was due to central nervous system 
maturation and early cochlear implantations should be done only after obtaining reliable 
behavioral hearing tests. 
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Hearing assessments in preterm babies with hyperbilirubinemia was also done by various 
authors. In a study conducted in late preterms with jaundice in Ganga Ram Hospital, Neonatal 
Division
18
, which included a total of 13 neonates it, was found that 6 out of 13 (46%) neonates 
had audiological abnormalities. It was concluded that auditory neuropathy spectrum is common 
in preterms with hyperbilirubinemia. Roberts JL et al
20 
in his study concluded that the abnormal 
results which were obtained in preterm neonates were due to immaturity of the brain. 
 In one another prospective study conducted in Dalhousie University, Canada by 
Jangaard et al
19
in newborns having bilirubin equal to or greater than 19 mg/dl, concluded that 
there was no increase in adverse effects reported previously to be associated with bilirubin 
toxicity. Associations with developmental delay, attention-deficit disorder, and autism were 
observed. 
Study by Heilmer  et al
21
 2010 at Department of Pediatrics, Medical College of 
Wisconsin, Milwaukee, Wisconsin, USA also concluded that no untoward outcome was found in 
term healthy infants with moderately severe non-hemolytic hyperbilirubinemia. 
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STUDY JUSTIFICATION 
The concepts of bilirubin toxicity remain highly controversial. The problem is that 
bilirubin levels that are toxic to one infant may not be toxic to another, or even to same infant in 
different clinical circumstances. Currently, major debate surrounds the toxicity of bilirubin in 
otherwise healthy full term infants and in premature LBW infants
5
. 
About 3% of the normal term infants have Bilirubin levels of more than 15 mg/dl
5
. No 
literature is available for the level above which bilirubin toxicity will occur in term neonate. 
This study was conducted to know the audiological and developmental outcome of 
normal term newborn with hyperbilirubinemia of 20 mg/dl or more, who have had intervention 
for management of hyperbilirubinemia and were not found to have any neurological abnormality 
by clinical examination during their stay in the hospital.  
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STUDY JUSTIFICATION 
The concepts of bilirubin toxicity remain highly controversial. The problem is that 
bilirubin levels that are toxic to one infant may not be toxic to another, or even to same infant in 
different clinical circumstances. Currently, major debate surrounds the toxicity of bilirubin in 
otherwise healthy full term infants and in premature LBW infants
5
. 
About 3% of the normal term infants have Bilirubin levels of more than 15 mg/dl
5
. No 
literature is available for the level above which bilirubin toxicity will occur in term neonate. 
This study was conducted to know the audiological and developmental outcome of 
normal term newborn with hyperbilirubinemia of 20 mg/dl or more, who have had intervention 
for management of hyperbilirubinemia and were not found to have any neurological abnormality 
by clinical examination during their stay in the hospital.  
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MATERIALS AND METHODS 
 
STUDY PLACE: 
1. GOVERNMENT R.S.R.M HOSPITAL, Chennai. 
Government RSRM Maternity hospital, is the maternity hospital of 
Government Stanley Medical College with an average number of about 
11000 deliveries per year. It has a Neonatal Intensive Care unit of level II 
care. It is an intramural NICU. 
2. INSTITUTE OF SOCIAL PEDIATRICS, Stanley medical college, Chennai. 
Institute of Social Pediatrics has a Neonatal Intensive Care Unit of Level 
II care which is an extramural NICU. 
STUDY DESIGN: 
                   Observational Study- longitudinal study 
STUDY PERIOD: 
 January 2010 to August 2011 
For the first 7 months, cases were registered. 
Follow up of the cases for the next one year.  
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SAMPLE SIZE AND SAMPLING METHOD: 
1. Consecutive sampling method7 was carried out for this study which is the 
addition of cases as and when neonates who met the inclusion criteria were 
admitted. 
2. 51 neonates were registered in this study. 
A total of 5793 cases were screened during the period of 7 months and 206 cases were 
found to have yellowish discoloration extending below knee level. Blood investigation for serum 
bilirubin was done and cases with serum bilirubin of equal to or more than 20 mg/dl were 
selected. A total of 51 neonates who fit into our inclusion criteria were registered for the study. 
  The exact percentage of normal term newborns with bilirubin values of 20 mg/dl and 
above was not available. The only statistics available was that 3% of the normal term infants 
have bilirubin Levels of more than 15 mg/dl
5
. On using EpiInfo software for calculating sample 
size assuming that about 1.5% of term newborns may have bilirubin values of 20mg/dl or more it 
was found that a sample size of 46 cases has a confidence interval of 95%.  Adequate sample 
size was obtained for this study.  
INCLUSION CRITERIA: 
 Term newborns with birth weight greater than 2500 grams 
 Hyperbilirubinemia equal to or more than 20mg/dl 
 
EXCLUSION CRITERIA: 
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 Sepsis 
 Prematurity 
 Term IUGR 
 Birth asphyxia- APGAR scores of 0-4 at 1 minute or 0-6 at 5 minutes 
 Babies with abnormal neurological examination 
 Overt endocrinological/metabolic problem/neurologic causes  
 Infants critically ill of any cause 
 Direct bilirubin greater than 15% of total serum bilirubin 
 History of ototoxic drug intake 
 Any congenital malformations 
 History suggestive of intrauterine infections  
 Family history of deafness. 
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METHODOLOGY: 
 5793 neonates who were born during the study period were screened. Neonates 
less than 2.5 kg were excluded. Term babies were screened for jaundice and cases 
with yellowish discoloration extending below knee were subjected to serum 
bilirubin levels. Babies with serum bilirubin of equal to or more than 20 mg/dl 
were further selected after applying the exclusion criteria. Babies fulfilling all the 
inclusion criteria were involved in the study. 
 Informed consent was obtained from parents. 
 Demographic data, antenatal history comprising of past history, family history of 
any hearing abnormality, history of any fever with rashes and lymphadenopathy, 
ototoxic drug exposure were recorded. 
 In natal history, history for term/preterm, birth weight, mode of delivery, and 
APGAR score were recorded. 
 Postnatal history of any NICU admission was noted. 
 Clinical examination was carried out for the babies. Babies with congenital 
malformations of the external ear, any abnormal facies and abnormal neurological 
examination were ruled out. 
 Bilirubin values were estimated and babies with total serum bilirubin levels of 
equal to or more than 20 mg/dl were included in the study. 
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 Mode of treatment was whether phototherapy or exchange transfusion was given 
was noted. 
 Cause for jaundice was noted. It was grouped into Rh incompatibility, ABO 
incompatibility and other causes. 
 Thyroid profile to rule out hypothyroidism was done. 
 Babies were planned for BERA (Brainstem Evoked Response Audiometry) after 
discharge and abnormality in BERA if present was noted. If abnormality was 
detected babies were referred to an audiologist. 
 BERA was repeated in the above population before 3 months to see if the changes 
persisted or had resolved.  
 Babies were also followed up using Trivandrum developmental screening chart 
(TDSC) at 3, 6, 9, 12 months of age and abnormalities, if any were noted. 
 All details were analyzed using appropriate statistical methods.  
STATISTICAL ANALYSIS: 
 Demographic variables like parity, sex of the baby, weight of the baby, mode of 
delivery, type of treatment and abnormal values in BERA were analyzed using 
SPSS 16 for windows and is given in percentage. 
 Association between bilirubin values with parity, sex of the baby, weight, mode 
of delivery and type of treatment was analyzed and given in percentage. 
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 For finding the association between bilirubin value and other parameters chi-
square test was used. 
 Values of chi-square more than 3.84 and p value of less than 0.05 were taken as 
statistically significant. 
 Logistic regression was done whenever necessary.  
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OBSERVATION AND RESULTS 
 Among the 51 babies who were included in the study after screening 5793 babies during 
the 7 months period 26 babies were born to primigravida (51%) and 25 were born to 
multigravid mothers (49%) (figure 2) 
 
 
 
 
 
Figure 2: Parity of the mothers of study population 
 
 
 
 
 
 
Figure 3: sex distribution in the study population 
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 From figure 3 which shows the sex distribution in the study population, male babies 
constituted 28/51 (54.9%) and female babies 23/51 (45.1%).  
 From figure 4 showing weight distribution, 25/51 babies (49%) were between 2500-2999 
grams, 21/51 (41.2%) were between 3000-3499 grams and 5/51 (9.8%) were of weight 
more than 3500 grams.     
 
 
 
 
 
Figure 4: distribution of weight in the study population 
 
 
Figure 5: Mode of delivery of the babies 
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 Analyzing the Mode of delivery (figure 5), 37/51 (72.5%) were born of normal vaginal 
delivery, 12/51 (23.5%) were born of LSCS and 2/51 (3.9%) were born of forceps 
delivery.  
 40/51(78.4%) had total serum bilirubin value between 20-24.9 mg/dl whereas 11/51 
cases had bilirubin value of more than 25 mg/dl (21.6%) (Figure 6). 
 
Figure 6: Serum Bilirubin values in study population 
 
 
 
Figure 7: Total serum bilirubin distribution against weight of the babies 
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 The mean total serum bilirubin value was 23.02 mg/dl, median 22.60 mg/dl, mode was 
21 mg/dl, with a standard deviation of 2.22 mg/dl, maximum value was 28 mg/dl and 
minimum value was 20 mg/dl. 
 12/51(23.5%) cases were due to Rh incompatibility, 17/51 cases (33.3%) due to ABO 
incompatibility and 22/51 (43.1%) due to other causes (Figure 8). 
 
Figure 8: cause of hyperbilirubinemia 
 
 From figure 9 showing treatment of the study population, 16/51 (31.3%) underwent 
exchange transfusion, whereas 35/51 (68.6%) had phototherapy. 
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Figure 9: treatment underwent by the study population 
 
 
Figure 10: BERA abnormalities at the time of discharge 
 BERA abnormalities were noted in 11/51 (21.6%) (Table 3) of the babies of 
which 4/11 had unilateral and 7/11 had bilateral abnormalities.  
 
Table 3: BERA abnormality at the time of discharge 
BERA  frequency percent 
Normal 
Abnormal 
total 
40 
11 
51 
78.4 
21.6 
100 
 
 
 In BERA done at the time of discharge, I-III interval was prolonged in 9/51 cases 
(17.6%) and was normal in 42/51 (82.4%) of the cases.(Table 4) 
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Table 4: I-III interval prolongation at discharge BERA 
 
BERA-I-III interval 
 
frequency 
 
percent 
Normal 
Abnormal 
 
42 
9 
51 
 
82.4 
17.6 
100 
 
 From Table 5, In BERA done at the time of discharge, I-V interval was prolonged 
in 11/51 (21.6%) of the cases (both unilateral and bilateral) and 7/11 had bilateral 
abnormalities. 
 
Table 5: I-V interval prolongation in BERA at discharge  
 
BERA–I-V interval 
 
frequency 
 
percent 
Normal 
Abnormal 
total 
40 
11 
51 
78.4 
21.6 
100 
 
 The mean age of BERA examination after discharging the babies was 10.18 days 
and median age was 10 days. Earliest age was 6 days and the maximum age of 
testing for the first time was 18 days. 
 On follow up BERA I-III wave abnormality was noted in only in 4/51 (7.8%)of the 
cases and 47/51 (92.1%) had normal waves(Table 6) 
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Table 6: BERA I-III interval prolongation on follow up 
BERA I-III interval frequency percent 
Normal 
Abnormal 
total 
47 
4 
51 
92.1 
7.8 
100 
 
 
 From table 7, on following up with repeat BERA I-V abnormality was persisting 
only in 5/51 (9.8%) and 46/51(90.2%) were normal. 
 
Table 7: BERA I-V interval prolongation on follow up 
BERA I-V interval frequency percent 
Normal 
Abnormal 
total 
46 
5 
51 
90.2 
9.8 
100 
 
 The mean age of repeat BERA was 77.55 days with a minimum age of 68 days 
and maximum age of 93 days. 
 
 On comparing total serum bilirubin values with both Unilateral/bilateral BERA 
abnormalities „p‟ value was found to be statistically significant („p‟ value-0.001)  
indicating higher the bilirubin value more chances of having BERA 
abnormality.(Table 8) 
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Table 8: Effect of value of bilirubin on BERA abnormality at the time of                    discharge 
 
Bilirubin 
BERA Total 
normal abnormal 
20-24.9 mg/dl 
>/= 25 mg/dl 
total 
36 
4 
40 
4 
7 
11 
40 
11 
51 
 
     „p’ value- 0.001- highly significant 
    Chi-square value-14.672- significant. 
 
 On comparing total serum bilirubin with final BERA abnormality 
(Table 9), „p‟ value was statistically significant („p‟ value- 0.008), even after 
reversal of abnormalities in some cases. 
 
Table 9: Effect of value of bilirubin on BERA abnormality at the time of follow 
up 
 
Bilirubin 
BERA Total 
Normal abnormal 
20-24.9 mg/dl 
>/= 25 mg/dl 
total 
39 
7 
46 
1 
4 
5 
40 
11 
51 
 
‘p’ value- 0.008- significant 
Chi-square test- 11.591 significant. 
 
 On comparing BERA abnormalities with the cause of jaundice, 
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(Table 10) chi-square value was not statistically significant 
(Chi- square value- 1.520), meaning the cause of jaundice doesn‟t relate to 
BERA abnormality. 
Table 10: Effect of cause of jaundice on BERA abnormality 
 
cause 
BERA  
Total Normal abnormal 
Rh incompatibility 
ABO incompatibility 
Others 
total 
9 
12 
19 
40 
3 
5 
3 
11 
12 
17 
22 
51 
 
Chi-square value- 1.520- not significant. 
 On comparing treatment with BERA abnormality, p value was found to be 
statistically significant („p‟ value- 0.002) (Table 11). 
 
Table 11: Effect of treatment on BERA abnormality 
 
Treatment 
BERA  
Total Normal abnormal 
Exchange transfusion 
Phototherapy 
total 
8 
32 
40 
8 
3 
11 
16 
35 
51 
„p’ value- 0.002- Statistically significant. 
Chi-square value- 11.141- significant. 
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 It was found in the study that there was reversibility in BERA abnormalities in   54.54% of 
the cases. Out of the 11 neonates who had BERA abnormality detected at the time of 
discharge only 5 had persisting BERA changes on follow up by third month. 
 On comparing BERA abnormality with weight of the baby(table 12)., Chi-square test did not 
give significant values (chi-square value- 0.174) 
 
Table 12: relation between weight of the infant and BERA abnormality 
 
Weight  
BERA  
Total Normal abnormal 
2500-2999 grams 
3000- 3499 grams 
>/= 3500 grams 
total 
19 
17 
4 
40 
6 
4 
1 
11 
25 
21 
5 
51 
 
Chi- square value- 0.174 – not significant 
 On comparing mode of delivery with BERA abnormalities, chi- square value was 0.887 
which is not significant (Table 13). Similarly on comparing BERA abnormalities with the sex 
of the baby, „p‟ value was 1.000 and is  not significant (Table 14). 
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Table 13: Effect of mode of delivery on BERA abnormality: 
 
Mode of delivery 
BERA  
Total Normal abnormal 
Vaginal 
LSCS 
forceps delivery 
total 
28 
10 
2 
40 
9 
2 
0 
11 
37 
12 
2 
51 
 
Chi-square value- 0.887- not significant 
Table 14: Effect of sex of the baby on bilirubin abnormality 
 
Sex of the baby 
BERA  
Total Normal abnormal 
Male 
Female 
total 
22 
18 
40 
6 
5 
11 
28 
23 
51 
‘p’ value- 1.000 not significant 
 On comparing parity with BERA abnormality „p‟ value was not significant („p‟ value- 
0.499).  
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 In conclusion significant p value was obtained between total serum bilirubin, mode of 
treatment and BERA abnormalities.  
 No significance was found in our study between BERA abnormalities and parity, sex, weight 
and mode of delivery. 
 Only two factors had significance with BERA abnormalities namely level of bilirubin and 
type of treatment. On computing logistic regression for these two factors following the result 
was obtained. 
 On performing a binary logistic regression in SPSS software, only bilirubin value [Exp(B) 
7.000] was found to be significant compared to treatment which had a Exp(B) value of 0.375 
and thus lost its significance. 
 This significance may be related to the fact that exchange transfusion is being done for 
higher bilirubin values and there has been a statistical significance between bilirubin value 
and BERA abnormality. 
 
FOLLOW UP OF INFANTS FOR DEVELOPMENTAL MILESTONES BY 
TRIVANDRUM DEVELOPMENTAL SCREENING CHART (TDSC): 
 On following up the babies with Trivandrum Developmental Screening Chart, at the third 
month for the attainment of various milestones, head control was achieved by all the 
neonates. (Table 15) 
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Table 15: TDSC abnormality on follow-up at third month 
TDSC frequency percent 
Normal 
Abnormal 
Missed cases 
51 
0 
0 
100 
0 
0 
 
 By the 6th month all infants who came for follow up achieved the required milestones 
and there was no developmental delay noted. Two cases were lost during the follow-
up (table 16). 
Table 16: TDSC abnormality on follow-up at sixth month 
TDSC frequency percent 
Normal 
Abnormal 
Missed cases 
49 
0 
2 
96.1 
0 
3.9 
 
 No developmental delay was found in infants by Trivandrum developmental 
screening chart during their ninth month visit. Five cases were lost during the follow-
up during this period of study (Table 17).  
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Table 17: TDSC abnormality on follow-up at ninth month 
TDSC frequency percent 
Normal 
Abnormal 
Missed cases 
46 
0 
5 
90.2 
0 
9.8 
 
 At the end of one year, no developmental abnormality was found in the infants using 
Trivandrum developmental screening chart. Five cases were lost to follow-up at the 
end of the study (Table 18). 
Table 18: TDSC abnormality on follow-up at one year 
TDSC frequency percent 
Normal 
Abnormal 
Missed cases 
46 
0 
5 
90.2 
0 
9.8 
 
 On analyzing total serum bilirubin value with any delay in attaining milestones, „p‟ 
value was not significant ('p'=1.000), even on assuming that all missing cases could 
have had developmental delay. Thus no significance was obtained between total 
serum bilirubin levels and the attainment of various milestones by using Trivandrum 
developmental screening chart for these infants. 
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DISCUSSION 
  Total number of newborns studied in our study was 51. In our study the BERA 
abnormality in normal risk term newborn with hyperbilirubinemia of 20 mg/dl or more was 
found to be 21.6%.  „p‟ value was significant on comparing bilirubin levels and BERA 
abnormalities. On following the developmental milestones of these newborn for one year using 
Trivandrum developmental screening chart no delay in milestones was noted.  There was a 
reversibility of BERA abnormalities in our study by 54.54%. 
NEONATAL HYPERBILIRUBINEMIA AND BRAINSTEM EVOKED 
RESPONSE AUDIOMETRY ABNORMALITY: 
  BERA abnormalities noted for the cases of hyperbilirubinemia were 21.6% at the 
time of discharge. Table 19 shows the comparison of our study with other studies done between 
the neonatal hyperbilirubinemia and BERA abnormality. 
 On comparing our study with studies made at various countries, Baradaranfar  et al
11
, 
2011 found a BERA abnormality of 25.7%, Lotfi  et al 
12
, 2010  had BERA abnormality of 
22.5%. Results of M.Oake, N Y Boo  et al
13
 was 22% and Ziang Z D  et al
24
2009 found BERA 
abnormality  in  28%  of  their  study population.  
All these studies are comparable to our study and the results are also comparable. 
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Table 19: Comparison of various studies of neonatal hyperbilirubinemia and BERA 
abnormality with our study 
Study Percentage of BERA 
abnormality 
 
Present  study 
 
 
INTERNATIONAL STUDIES 
 
Baradaranfar  et al
11
, 2011 
  
Lotfi  et al
12
, 2010 
 
 
M.oake, N Y Boo  et al 
13
1994 
 
Ziang Z D  et al
24
, 2009 
 
Chen W X  et al
14
, 2006 
 
 
NATIONAL STUDIES 
 
Mukhopadhyay  et al
15
, 
2011 
 
Sharma  et al
25
, 2006 
 
Agwarwal V K  et al
16
, 
1998 
 
 
21.6 
 
 
 
 
25.7 
 
22.5 
 
 
22 
 
28 
 
9.37 
 
 
 
 
76 
 
 
73.3 
 
56.7 
   
 62 
 
 On comparing with Chen W X et al
14
 2006, the BERA abnormality found on the study 
was 9.37% which is lower than our study. 
 Regarding studies done in India, no studies were available from South India. Studies have 
been done only in Northern India till now. On comparing the study done by Mukhopadhyay  et 
al
15
 2011, the BERA abnormality found by that study was 76%. The possible explanation for the 
disparity could be because of the fact that the study population included in the study were babies 
of more than 35 weeks of gestation (preterm also) and the mean serum bilirubin value of the 
study was 37mg/dl which is far higher than our study which had a mean serum bilirubin of 23.02 
mg/dl. 
 On comparing with another Indian study, Sharma et al
25
, 2006, the BERA abnormality 
was 73.3%. A possible explanation for this disparity may be because in this study the BERA was 
conducted at the time of peak bilirubin levels and in our study it was done only at discharge. 
CORRELATION BETWEEN BERA ABNORMALITIES AND SERUM 
BILIRUBIN LEVELS: 
In our study there was a significant „p‟ value for the association between serum total 
bilirubin levels and BERA abnormalities. Our study comparison with other studies is shown in 
Table 20. 
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Table 20: Comparison with other studies of correlation between BERA abnormalities and 
serum bilirubin levels 
 
Study 
 
Result 
 
Mukhopadhyay  et al
15
, 2011 
Agarwal  et al
16
, 1998 
Silva  et al
26
, 2009 
Ziang ZD  et al
24
, 2009 
Present study 
 
Significant association 
Significant association 
No correlation 
No correlation 
Significant p value 
 
 
Mukhopadhyay et al
15
, 2011 and Agarwal et al
16
1998 also had similar results suggesting 
association between serum bilirubin levels and BERA abnormalities. 
 Ziang Z D  et al
24
, 2007, on his study on term infants with hyperbilirubinemia found that 
although acute ototoxic effect of hyperbilirubinemia tends to be more significant at higher rates 
than lower rates, auditory impairment do not closely increase with increase in serum bilirubin 
values. 
 Studies by Silva et al
26 
and Ziang Zd et al
24
, 2009 did not find any association between 
serum bilirubin and BERA abnormalities. 
  
 64 
 
REVERSIBILITY OF BERA ABNORMALITIES: 
Table 21: Comparison between our study and others about reversibility of 
 BERA abnormalities. 
 
Study 
 
Result 
 
 Present study 
Psarommatis et al
27
, 
2011 
Sharma  et al
25
, 2006 
Chen W X  et al
14
, 2006 
 
 
54.54% recovery 
64.2%  recovery 
 
68.18% recovery 
72.72%  recovery 
 
  In our study BERA abnormality was reversed in 54.54% of the babies. Comparing this 
with other studies( Table 21) , Psarommatis et al
27
, 2011 in his study found that 64.2% of the 
babies with hyperbilirubinemia with BERA abnormalities reverted on further follow up. 
  On comparing with the study by Chen W X et al
14 
study, 2006, BERA abnormality 
returned to normal in about 72.72% of the babies. These babies were followed up to 2 years of 
age and at the end of 2 years 72.72% babies with initial abnormal BERA had normal BERA. 
  On comparing with the study done by Sharma et al
25
, 2006, BERA abnormality reversed 
in 68.18 % of babies. 
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FOLLOW-UP OF DEVELOPMENTAL MILESTONES: 
Table 22: Comparison of developmental outcome of our study and others 
 
Study 
 
Result 
Thomas B Newmann et al
17
, 2006 
 
 
Heilmer et al
21
, 2010 
 
Chen W X  et al
14
, 2006 
 
 
Agarwal  et al
16
, 1998 
 
Present study 
 
Not associated with any abnormal 
neurodevelopmental outcome 
 
No abnormality was noted 
 
3.9% had abnormal neurodevelopmental 
outcome 
 
10% had abnormal DDST 
 
NO delayed milestones were noted in any 
cases. 
 
 In our study developmental screening was done with Trivandrum Developmental 
Screening Chart (TDSC) and all babies passed the test successfully. 
Comparing our study with study done by Thomas B Newmann et al
17
, 2006, who also 
found that there was no abnormal Neurodevelopmental outcome for babies with bilirubin value 
of more than 25 mg/dl who were treated with exchange transfusion. In this study 
neurodevelopmental outcome was assessed by child psychologists by Wechsler Preschool and 
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Primary Scale of Intelligence–Revised (WPPSI-R) and the Beery–Buktenica Developmental Test 
of Visual-Motor Integration and no abnormality were detected in the children. 
Study by Heilmer et al
21
 2010 at Department of Pediatrics, Medical College of 
Wisconsin, Milwaukee, Wisconsin, USA also concluded that there was no untoward outcome 
found in term healthy infants with moderately severe non-hemolytic hyperbilirubinemia. 
Assessment was done by Bailey Scales of Infant development II test, speech evaluation, 
behavioral hearing test and a neurological examination. 
On comparing our study with that done by Chen W X et al
14
 it was found that 3.6% of the 
babies on follow-up were found to have neurodevelopmental abnormality. 
In this study all had regular physical, neurologic, visual, and auditory evaluation until 3 years of 
age. 
Study by Agarwal et al
16
 1998 found that the abnormality was 10%. But in this study 
Denver Developmental Screening Test was used and not Trivandrum developmental screening 
chart.   
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CONCLUSION 
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CONCLUSION 
Analysis was done for auditory abnormalities for term  newborn with bilirubin values of 
20mg/dl or more, who have had interventions for the management of hyperbilirubinemia and had 
no abnormal neurological examination during their stay in the hospital. Analysis of the study 
results show that BERA abnormalities were present in 21.6% of term newborns with 
hyperbilirubinemia as the only risk factor at the time of discharge. 
Though there is a reversibility of BERA abnormality in 54.54% of these neonates with 
hyperbilirubinemia, abnormality still persists in 9.8% of these neonates by 3 months of  age. 
No obvious developmental delay was found out by using Trivandrum developmental 
screening chart in these infants on one year followup. 
It is therefore necessary that all term newborns with bilirubin values of 20mg/dl or more, 
even if not associated with any other risk factor, be screened with BERA and these babies be 
followed up regularly to find if they have persistent abnormalities so that they can be effectively 
managed.. 
No significant association was found between BERA abnormalities and sex, weight and the 
cause of hyperbilirubinemia. 
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LIMITATIONS AND SUGGESTIONS 
 BERA was done after discharge and not at peak of hyperbilirubinemia due to 
operational difficulties. 
 Follow up was done for one year only. Further follow-up would be helpful for 
determining long term effects of hyperbilirubinemia in normal risk term 
newborns. 
 Suggestions : 
 The study can be performed with lower bilirubin value to know whether 
further lower levels may have BERA abnormalities. 
 Period of follow up could be longer. 
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APPENDIX – 1 
PROFORMA 
FOLLOW UP OF TERM NEWBORN WITH HYPERBILIRUBINEMIA FOR ONE YEAR - 
FOR DEVELOPMENTAL AND AUDITORY ABNORMALITY 
 Baby of:                                                                                       name: 
                                                                                                      Sex: 
                                                                                                      Address: 
 
                                                                                                      Phone number: 
Antenatal history: 
               Score: G   P   L   A: 1. Primigravida    2. Multigravida 
               Past history:             1. Significant       2. Not significant 
               Family history of any hearing impairment at childhood period: 
1. Significant     2. Not significant 
               Present pregnancy: 
H/o fever 1st trimester: 
        2
nd
 trimester: 
 3
rd
 trimester:        1. Significant 2. Not significant 
        H/o any radiation exposure: 1. Significant 2. Not significant 
   H/o any systemic diseases:   1. Significant 2. Not significant 
     H/o any ototoxic drug ingestion: 1. Significant 2. Not significant 
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Natal history: 
                         Term                                                       :       yes/no 
                         Birth wt: <2500gms/ >2500 gms           ;              gms 
1. 2500- 2499 grams 
2. 3000-3499 grams 
3. 3500 grams and above 
                         Mode of delivery                                   :       
1.  vaginal 
2.  LSCS 
3.  forceps 
4. vacuum 
                         Whether cried immediately after birth  :       yes /no 
                         APGAR                                                 :       1” 
                                                                                                5” 
Postnatal history 
                       H/o not crying immediately after birth:           yes/no 
                       H/o NICU admission                              :        yes/no 
                       If yes duration                                        :             
Clinical examination: 
                      Jaundice level by clinical examination: Below Knee 1. Yes   2. No  
                      Any congenital abnormality      :       1. Yes              2. No 
          Abnormal Clinical Examination:       1 Yes               2. No 
Bilirubin Level: 
Date    
Bilirubin level    
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                                   :     
Whether exchange transfusion done                             :         1.Yes            2. No 
 
Whether bilirubin level >20mg%                                 :          1. Yes            2. No 
 
 Thyroid profile         : 1. Normal                             2. abnormal 
 
Cause of hyperbilirubinemia  
  1.     Rh   incompatibility 
  2.     ABO incompatibility 
  3.     Others 
 
BERA: 
Done on day                       : 
Result                                 :                                           1.  Normal           2. Abnormal 
                                            I-III  wave abnormality      1.  Normal           2.Abnormal 
                                            I-V  wave abnormality       1. Normal            2.Abnormal 
                                            Other comments: 
 
If abnormal repeat BERA:                                             1. Normal            2. Abnormal 
                                  Date: 
    I-III wave abnormality          1.Normal             2. Abnormal 
    I-V wvae abnormality           1.Normal              2.Abnormal 
                                         Other comments: 
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Trivandrum Developmental Screening Test: 
 
1
st 
 follow-up 
                     Date                         : 
                     Attained milestones:  1)  yes  2)   no 
2
nd
 follow-up   
                    Date                
                    Attained milestones:  1)  yes  2)   no 
 
3rd follow-up 
                     Date  
                      Attained milestones:  1)  yes  2)   no 
 
4
th
 follow-up 
                      Date                                                                                                                                                                                                     
                      Attained milestones:  1)  yes  2)   no 
 
 
Inference 
  BERA                          :                 1.   Normal  
1. Abnormal 
  TDST                           :                  1. Normal  
                                     2.  Abnormal 
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parity sex wt MOD bilirubin treatment cause A B C D E F G tdst threemonths sixmonths ninemonths twelvemonths
b/o nazeema 2 1 1 3 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/omuniamma 1 2 2 1 2 1 2 2 2 2 2 2 2 2 1 1 1 1 1
b/o kowsalya 2 1 1 2 2 1 1 1 2 2 2 1 1 1 1 1 1 1 1
b/o kumari 1 1 1 1 2 1 2 1 1 1 1 1 1 1 0 1 0 0 0
b/o parveen 2 1 1 1 2 1 3 2 2 2 2 1 2 2 1 1 1 1 1
b/o bhuvaneshwari 2 2 2 1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1
b/o tharif 2 1 2 1 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o lalitha 1 1 3 2 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o meena nandakumar 1 1 1 1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1
b/o vijaya 2 2 2 1 1 1 2 2 2 1 2 1 2 2 1 1 1 1 1
bv/o selvi 1 2 1 1 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o shobana 1 1 1 1 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o satya 1 1 2 2 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o parimala 1 2 1 2 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o najma 1 2 1 1 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o kalaiarasan 2 2 3 1 2 1 2 2 2 2 2 1 1 1 1 1 1 1 1
b/o kalpana 1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
b/o rekha 2 2 1 1 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o loga 1 2 1 1 1 2 3 1 2 2 2 2 1 1 1 1 1 1 1
b/o murugadha 1 1 1 1 1 2 2 2 2 2 2 1 1 1 0 1 1 0 0
b/o rekha 2 2 1 1 2 1 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o ammamulu 2 2 1 1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1
b/o anushya 1 2 2 1 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o sabiyamani 1 2 1 1 2 1 1 1 2 2 2 1 1 1 1 1 1 1 1
b/o nasrin 1 2 2 1 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o sangeetha 2 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1
APPENDIX- 2 
MASTER CHART 
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parity sex wt MODbilirubintreatmentcauseA B C D E F G tdst threemonths sixmonths ninemonths twelvemonths
b/o nargese 1 1 1 1 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o mohana 2 2 2 1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1
b/o anitha 2 2 2 1 1 2 1 1 1 1 1 1 1 1 0 1 0 0 0
b/o kalaiselvi 2 2 2 1 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o rita 1 1 2 2 2 1 1 2 2 2 2 2 2 2 1 1 1 1 1
b/o padma 2 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1
b/o karpagam 2 1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1
b/o roja 1 2 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1
b/o nathiya 1 1 2 1 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/oshobana 1 1 2 1 1 2 3 1 2 1 2 1 1 1 1 1 1 1 1
b/o sangeetha 1 1 1 1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1
b/o gunaselvi 2 1 1 1 1 1 2 1 1 1 1 1 1 1 0 1 1 0 0
b/o latha 2 2 1 1 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o amutha 2 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1
b/o pavithra 2 2 2 2 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1
b/o bindhu 1 2 3 2 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o devagi 2 2 3 2 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o bhuvaneshwari 1 1 3 1 1 2 2 1 1 1 1 1 1 1 0 1 1 0 0
b/o vighneshwari 2 1 2 3 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1
b/o maheshwari 2 1 2 2 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1
b/o jeeva 2 1 2 1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1
b/o syed faridha 1 1 2 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1
b/o dhanalakshmi 2 2 2 2 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1
b/o deepa 1 1 1 1 2 1 2 2 2 2 2 2 2 2 1 1 1 1 1
b/o nalini 1 1 2 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1
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APPENDIX – 3 
KEYS TO MASTER CHART 
Parity 
1- Primigravida 
2- Multigravida 
Sex of the newborn 
1- Male 
2- Female 
Weight of the baby 
1- 2500-2999 grams 
2- 3000- 3499 grams 
3- 3500 grams and above 
MOD- mode of delivery 
1- Vaginal delivery 
2- LSCS 
3- Forceps 
Bilirubin – serum total bilirubin 
1- 20- 24.9 mg/dl 
2- 25 mg/dl and above 
Treatment  
1- Exchange transfusion 
2- Phototherapy 
Cause of hyperbilirubinemia 
1- Rh incompatibility 
2- ABO incompatibility 
3- Other causes 
A – only bilateral abnormality 
1- Normal 
2- Abnormal 
B – both unilateral and bilateral abnormality included 
1- Normal 
2- Abnormal 
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C – I-III wave prolongation- BERA at discharge 
1- Normal 
2- Abnormal  
D – I-V wave prolongation- BERA at discharge 
1- Normal 
2- Abnormal  
E- I-III wave prolongation- BERA at follow- up 
1- Normal 
2- Abnormal 
F – I-V wave prolongation- BERA at follow- up 
1- Normal 
2- Abnormal 
G – BERA result on follow-up 
1- Normal 
2- Abnormal 
TDST- Trivandrum Developmental Screening Test Result 
0-   Missed cases 
1-  Normal 
2-   Abnormal 
Threemonth- 3
rd
 month TDST result 
0-   Missed cases 
1- Normal 
2- Abnormal 
Sixmonth- 6
th
 month TDST result 
0-  Missed cases 
1- Normal 
2- Abnormal 
 
 
 
Nine month- 9
th
 month TDST result 
0-  Missed cases 
1- Normal 
2- Abnormal 
Twelvemonth- one year TDST result 
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0-   Missed cases 
1- Normal 
2- Abnormal 
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APPENDIX – 4 
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APPENDIX – 5 
TRIVANDRUM DEVELOPMENTAL SCREENING CHART 
1- Rh i 
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APPENDIX – 6 
BRAINSTEM EVOKED RESPONSE AUDIOMETRY 
 
30- Rh i 
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APPENDIX – 7 
CONSENT FORM 
  
59- Rh i 
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APPENDIX – 8 
ABBREVIATIONS 
STB – Serum Total  Bilirubin 
LBW- Low Birth Weight 
BERA- Brainstem Evoked Response Audiometry 
ABR- Auditory Brainstem Response 
IUGR- Intra Uterine Growth Retardation 
TDSC- Trivandrum Developmental Screening Chart  
DDST - Denver Developmental Screening  Test 
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